Document Classification

Section Type: RESULTS

Text: The addition of 2 or 4 mg/d of rosiglitazone significantly decreased the C-reactive protein level (vs baseline : -22. 0 % [P <. 001] and -34. 2 % [P <. 001] ; vs placebo : -22. 2 % [P =. 003] and -32. 0 % [P <. 001]) and fibrinogen (vs baseline : -10. 5 % and -12. 0 % [both P <. 001] ; vs placebo : -7. 9 % [P =. 002] and -7. 6 % [P =. 004]), while 4 mg/d of rosiglitazone significantly reduced matrix metalloproteinase 9 levels (vs baseline : -17. 1 % [P =. 007] ; vs placebo : -23. 3 % [P <. 001]).